|
MechanismCD276 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismImmunomodulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismCD276 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase I Clinical Trial of SDTM001 Injection as Adjuvant Treatment for NSCLC Patients With Driver-gene-negative and Negative PD-L1 Expression After Radical Surgical Resection
The goal of this clinical trial is to evaluate the safety profile and tolerability of SDT-M001 injection in NSCLC patients with driver-gene-negative and negative PD-L1 expression after radical surgical resection; to determine the recommended Phase II dose (RP2D).
100 Clinical Results associated with Cytocraft Biopharmaceutical Co., Ltd.
0 Patents (Medical) associated with Cytocraft Biopharmaceutical Co., Ltd.
100 Deals associated with Cytocraft Biopharmaceutical Co., Ltd.
100 Translational Medicine associated with Cytocraft Biopharmaceutical Co., Ltd.